US biotech firm Chelsea Therapeutics’ (Nasdaq: CHTP) has named Joseph Oliveto as president and chief executive officer and a member of the company's board of directors, effective January 22. 27 January 2014
Privately-held US drugmaker Purdue Pharma has appointed Mark Timney as president and chief executive. He succeeds John Stewart, who has retired from Purdue. 27 January 2014
Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Susan Kilsby will become non-executive chairman, replacing Matthew Emmens who is retiring at the company’s AGM on April 29. 23 January 2014
French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision to set up its own oncology team to commercialize Somatuline Depot (lanreotide) in neuroendocrine tumors (NETs) in the USA. 22 January 2014
Takeda Pharmaceutical, Japan’s largest drug company, has appointed Emiliangelo Ratti as head of its CNS Drug Discovery Unit, Pharmaceutical Research Division. 15 January 2014
US generics and specialty drugmaker Actavis has announced an updated business structure for its US Specialty Brands business designed to maximize the company's newly-strengthened position in key therapeutic areas and position it for continued long-term growth. 14 January 2014
Swiss drug major Novartis said on Sunday (January 12), that Herve Hoppenot, president of Novartis Oncology, will leave the company with immediate effect having decided to “pursue a career opportunity outside of the organization.” 13 January 2014
German privately-owned pharma company Priaxon AG has appointed Constance Hoefer as chief development officer (CDO) to oversee non-clinical and early clinical development. 9 January 2014
Somewhat sooner than expected, Isael’s Teva Pharmaceutical Industries, the world’s largest generics drugmaker, has confirmed recent reports, saying that Erez Vigodman has been appointed president and chief executive, effective February 11. 9 January 2014
Merck Serono, the biotech unit of Germany’s Merck KGaA (MRK: DE), has named Steven Hildemann as global chief medical officer and head of global medical and safety for the Merck Serono division. 9 January 2014
US biotech company Promedior has announced that industry veteran William Hodder has joined the company as Vice President of Business Development. 8 January 2014
US biopharmaceutical company Blend Therapeutics has appointed pharmaceutical industry veteran Richard Wooster as chief scientific officer. 7 January 2014
Speculation is mounting that Israel’s Teva Pharmaceutical Industries is about to appoint a new chief executive, after ousting 18-month incumbent of the post, Jeremy Levin, last October. 7 January 2014
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024